Pfizer, Inc. · NYSE:PFE
Pfizer — UBS Presentation (September 2006)
13 slides from Pfizer's conference presentation, Sep 26, 2006
Slide 1: Pfizer presenters
David Shedlarz Vice Chairman Marie-Caroline Sainpy Senior Vice President, Marketing Michael Berelowitz Senior Vice President, Medical Alan Levin Chief Financial Officer Valid as of September 26, 2006
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
Forward-Looking Statements and Non- GAAP Financial Measures The discussion today includes forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in our 2005 Annual
Slide 3: New Leadership for Changing Times
New Leadership for Changing Times New Approach to Changing Environment Strong Company to Capitalize on Change Spirit of Small Company Transforming Our Business Valid as of September 26, 2006 3
Slide 4: New Approach to Changing Environment
New Approach to Changing Environment Pharmaceutical Industry Buffeted by Change z Technology z Consumer Preferences z Regulatory Environment Successful Companies Understand, Adapt to, and Anticipate Change Years in Advance Pfizer Must Now Embrace Change to Shape Healthcare System of Future Val
Slide 5: Strong Company to Capitalize on Change
Strong Company to Capitalize on Change Industry-Leading R&D Pipeline, Capabilities State-of-Art Production Facilities World-Class Sales Force Unmatched Financial Strength/ Operating Flexibility Valid as of September 26, 2006 5
Slide 6: Strong Company to Capitalize on Change: Uses of Cash
Strong Company to Capitalize on Change Uses of Cash Over Next 30 Months Pfizer Expects: $34 Billion z Cash Flow From Operations Plus z Proceeds of Consumer Healthcare Divestiture $17 Billion (Acquisitions) Minus z Dividends and Capital Expenditures To Total z $34 Billion Up to $17 Billion – Will Hav
Slide 7: Spirit of Small Company
Spirit of Small Company Success in Marketplace Requires Speed, Agility, Entrepreneurship Pfizer Is Succeeding at Getting Smaller: z Removing Layers of Bureaucracy z Designing More Integrated, Leaner Organization z Accelerating Decision Making z Exercising Clear Lines of Authority/Accountability
Slide 8: Transforming Our Business: Physician/Patient Support Programs
Transforming Our Business Physician/Patient Support Programs Chantix z Enormous Market Potential: At Current Trends, 500 Million People Currently Alive Will Die From Smoking-Related Illness z Tapping Market Potential Requires User Support: Behavior Modification Program Key to Success in Highly Add
Slide 9: Transforming Our Business: Licensing and Development Deals
Transforming Our Business: 12 Months of Licensing and Development Deals Bayer Compounds (BAY 74-4113) for Obesity and Diabetes Bioren Technologies to Discover and Optimize Monoclonal Antibodies Exubera (Inhaled Insulin) Worldwide Rights Acquired From sanofi- aventis Fesoterodine (Overactive
Slide 10: Transforming Our Business: Oncology
Transforming Our Business Oncology Current Presence: Camptosar, Ellence, Aromasin Successful January 2006 U.S. Launch of Sutent z Approved for Metastatic Renal Cell Carcinoma (U.S. First-Line) and Imatinib-Resistant GIST z Recently Approved for RCC and GIST in Europe z In Development for Breast,
Slide 11: Transforming Our Business: Biotherapeutics
Transforming Our Business Biotherapeutics Current Pfizer Biologic Products Projected to Generate $1.5 Billion in 2006 Revenues Target Tripling of Revenue From Biologics by 2010 Exubera: A Revolutionary Approach to Insulin Delivery z Provides Efficacy Comparable to Subcutaneous Insulin With Com
Slide 12: New Leadership for Changing Times
New Leadership For Changing Times New Approach to Changing Environment Strong Company to Capitalize on Change Spirit of Small Company Transforming Our Business Valid as of September 26, 2006 12
Slide 13: Valid as of September 26, 2006
Valid as of September 26, 2006